The novel agent prexasertib showed promising activity and was reasonably well tolerated in a phase II study of high-grade, heavily pretreated, BRCA wild-type serous ovarian carcinoma.
A diet rich in foods known to cause inflammation may increase the risk for colorectal cancer by about one-third, according to the results of a newly published study.
Treatment with hyperthermic intraperitoneal chemotherapy along with cytoreductive surgery resulted in better survival outcomes than surgery alone in patients with stage III epithelial ovarian cancer, according to a new study.
The FDA has expanded the approval of afatinib (Gilotrif) to include the first-line treatment of metastatic non–small-cell lung cancer patients whose tumors have non-resistant EGFR mutations, including three newly identified substitution mutations.
A test measuring circulating tumor cells in the bloodstream was able to accurately detect early-stage colorectal cancers, according to the results of a new study.
Adding abiraterone plus prednisone to ADT improves patient-reported outcomes and quality of life in patients with metastatic castration-naive prostate cancer.
Using gene expression profile tests like Oncotype DX to inform treatment decision-making for breast cancer is likely to be less cost-effective in community oncology practice than previous estimates had suggested.
Adjuvant everolimus did not improve disease-free survival in patients with DLBCL and confirmed complete response after 1 year of rituximab treatment.
Continuing letrozole therapy after 5 years of aromatase inhibitor therapy did not worsen quality-of-life measures in patients with HR-positive breast cancer.
A new analytical tool called topographic single-cell sequencing can reveal a direct genomic lineage between in situ and invasive tumor subpopulations, which may help decipher how and why some DCIS become invasive.